Magro, FernandoLopes, SusanaSilva, MarcoCoelho, RosaPortela, FranciscoBranquinho, DiogoCorreia, LuísFernandes, SamuelCravo, MaríliaCaldeira, PauloSousa, Helena TavaresPatita, MartaLago, PaulaRamos, JaimeAfonso, JoanaRedondo, IsabelMachado, PatríciaPhilip, GeorgeLopes, JoanneCarneiro, Fátima2019-10-082019-10-082019http://hdl.handle.net/10400.1/12800Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab.engEndoscopic activityGolimumabHistological activitySerum soluble ST2Ulcerative colitisSoluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumabjournal article10.1177/1756284819869141